ADA2 and gastric adenocarcinoma: ADA2 was significantly increased in esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), LAML, OV, PAAD, skin cutaneous melanoma (SKCM), and STAD (Figure 1D).